Understanding EPO and JAK2 Tests
EPO (erythropoietin) is a hormone test that measures how your kidneys are telling your bone marrow to make red blood cells, while JAK2 is a genetic test that looks for a specific mutation that causes your bone marrow to overproduce blood cells on its own.
What is EPO (Erythropoietin)?
EPO is a hormone naturally produced by your kidneys that acts like a messenger telling your bone marrow to produce more red blood cells. When you measure EPO levels in the blood:
- Normal/High EPO: Your kidneys are appropriately responding to low oxygen or blood loss by signaling for more red blood cells
- Low EPO: Suggests your body doesn't need more red blood cells (because you already have too many), or there's a problem with the bone marrow making cells without proper signals
How to Explain EPO to Patients:
"Think of EPO like a thermostat in your house. When it's cold, the thermostat tells the heater to turn on. Similarly, when your body needs more red blood cells, your kidneys release EPO to tell your bone marrow to make more. We're checking if your thermostat is working correctly or if something else is causing high blood counts."
In polycythemia vera (PV), EPO levels are typically very low (≤3.3 mIU/mL, with levels ≤1.99 mIU/mL being 100% predictive of PV) because the bone marrow is overproducing red blood cells without needing the kidney's signal 1. Low EPO has a positive predictive value of 92.1% for true polycythemia 1.
What is JAK2?
JAK2 (Janus kinase 2) is a gene that normally helps control blood cell production. The JAK2 V617F mutation is an abnormal change in this gene that causes uncontrolled blood cell production, particularly red blood cells.
How to Explain JAK2 to Patients:
"JAK2 is like a switch that controls how many blood cells your body makes. Normally, this switch turns on and off as needed. The JAK2 mutation we're testing for is like a switch that gets stuck in the 'on' position, causing your bone marrow to constantly make too many blood cells even when you don't need them. This mutation is found in about 95% of people with polycythemia vera."
Clinical Significance
The JAK2 V617F mutation is found in:
- ≥95% of polycythemia vera patients
- ~60% of essential thrombocythemia patients
- ~60% of primary myelofibrosis patients 2
The combination of both tests provides powerful diagnostic information 3:
- Hematocrit >52% (males) or >48% (females) PLUS JAK2 V617F mutation has 79% sensitivity and 97% specificity for PV
- Adding low EPO levels increases sensitivity to 83% while maintaining 96% specificity
Important Clinical Caveats:
While low EPO strongly suggests PV, elevated EPO does not exclude it 4. Rare cases of PV with elevated EPO have been documented, so if clinical suspicion remains high (symptoms like headache, thrombosis, elevated hemoglobin), JAK2 testing and bone marrow biopsy should still be pursued 4.
JAK2 mutation testing should screen exons 12-15, not just the V617F mutation, as 2-4% of PV patients have JAK2 exon 12 mutations instead 2, 5.
Practical Testing Approach
When evaluating suspected polycythemia:
- Check hemoglobin/hematocrit first: Men >16.5 g/dL or women >16.0 g/dL warrant investigation
- Order both EPO and JAK2 V617F simultaneously for optimal diagnostic accuracy
- Interpret together: Low EPO + positive JAK2 = highly specific for PV
- If JAK2 V617F negative: Consider JAK2 exon 12 mutations (2-4% of PV) and other causes of erythrocytosis 5
The diagnostic accuracy of EPO measurement depends on the assay used - chemiluminescent-enhanced enzyme immunoassay (CEIA) performs better than radioimmunoassay (RIA) with area under the curve of 0.87 versus 0.76 3.